Daniel Amante

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Daniel Amante sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials none currently recruiting 2 completed upper half by trial count

Daniel Amante: 2 sponsored US clinical trials, none currently recruiting.

Daniel Amante sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 2 trials.

Mid-pack sponsor footprint

Daniel Amante is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Indexed trials (enrollment closed)

2 total, page 1 of 1

COMPLETED NA

DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

NCT05583877
COMPLETED NA

Development and Feasibility Testing of DM-BOOST Intervention.

NCT04710940

Therapeutic Areas

Diabetes Mellitus, Type 2 2

How the Daniel Amante archive is shaped

2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Diabetes Mellitus, Type 2 (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Daniel Amante: archived-pipeline peers nationwide

Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Daniel Amante sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Daniel Amante1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Daniel Amante sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Daniel Amante sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Daniel Amante page

2 registered trials is a research-attention snapshot, not an endorsement of Daniel Amante or any single study.

  • None of Daniel Amante's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Diabetes Mellitus, Type 2 is the condition Daniel Amante studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Daniel Amante pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.